MICC Research Newsletter 2020 Vol 2 Iss 1 (1)

Page 8
MICC Newsletter
Eligibility Criteria’s:
• Inclusion Criteria
– Unilateral operable breast cancer
– Clinical/Radiological N+, or T2/T3 tumours
– Female aged >=18 years
• Exclusion
– Previous history of excision biopsy of the primary tumour
– History of other epithelial/ mesenchymal malignant tumours except BCC/SCC of skin
Critical Analysis of Recent Clinical Trial
Revisiting adjuvant ovarian suppression in premenopausal breast cancer patient
Dr Waseem Abbas
Consultant - Medical Oncology
Max Super Speciality Hospital, Shalimar Bagh
In postmenopausal women, better results are seen with AI compared to tamoxifen; can the same results be
seen in premenopausal women? In young, premenopausal women more recurrences occur during the first 5
years of treatment. These young premenopausal women require aggressive management.
In SOFT and TEXT, the clinical parameters on which women, who did not require adjuvant chemotherapy
and were considered low-risk, were selected remains unclear. The selection criteria defining low-risk were
not published. Presumably, the parameters must have been elderly, small breast primary, well differentiated,
lymph node negative, ER, PR Positive, and Her2 Neu negative. Either, gene expression profile can be used to
select such patients with low-risk. These patients did very well in the updated analysis by Francis et al. [1]
Tamoxifen% Tamoxifen Exemestene
plus OFS% plus OFS%
Overall survival 98.8 97.9 97.7
RFS 97.8 97.8 99.3
Table 1
RFS=Recurrence Free Survival; OFS=Ovarian Function Suppression